Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review

Benedikt Pleuhs, Katherine G Quinn, Jennifer L Walsh, Andrew E Petroll, Steven A John, Benedikt Pleuhs, Katherine G Quinn, Jennifer L Walsh, Andrew E Petroll, Steven A John

Abstract

Increasing prescription of pre-exposure prophylaxis (PrEP) is imperative to ending the HIV epidemic in the United States. The objective of this review was to identify health care provider barriers to PrEP implementation. A systematic review was conducted in February 2019 using PubMed to identify barriers to PrEP prescribing practices in the United States. Targeted search terms surrounding PrEP and providers resulted in 222 original studies, 28 of which were ultimately included in our review, with data collected between 2011 and 2018. Six themes were identified across reviewed studies: (i) a lack of PrEP knowledge, (ii) the presence of the Purview Paradox, which refers to discordance in beliefs between HIV specialists and primary care providers on who should prescribe PrEP, (iii) concerns about PrEP costs, (iv) concerns about behavioral and health consequences, (v) interpersonal stigma, and (vi) concerns about patient adherence. A majority of providers were lacking knowledge regarding PrEP, resulting in discomfort in prescribing PrEP, or limited awareness and understanding of PrEP clinical guidelines. Discrepant opinions were identified regarding whether PrEP was best managed within primary care or specialty clinics. Other barriers included concerns about cost, patient adherence, and follow-up maintenance care. Finally, concerns about risk compensation and discomfort discussing sexual activities with patients who would benefit most from PrEP were apparent. Additional work is needed to prepare providers to prescribe and manage patients on PrEP, optimize PrEP delivery, and reduce provider bias. Future research is needed to identify providers' attitudes and beliefs regarding innovations in PrEP dosing, task shifting, and novel strategies for PrEP care.

Keywords: HIV; pre-exposure prophylaxis; prescription; providers.

Conflict of interest statement

A.E.P. reports receiving research funding from Gilead Sciences, Inc. All other authors declare no competing financial interests.

Figures

FIG. 1.
FIG. 1.
Flow diagram for systematic review of the literature related to PrEP barriers, 2011–2018. PrEP, pre-exposure prophylaxis.

Source: PubMed

Подписаться